Alessandra Leone
Alessandra Leone
Unknown affiliation
No verified email
TitleCited byYear
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT
F Bruzzese, A Leone, M Rocco, C Carbone, G Piro, M Caraglia, ...
Journal of cellular physiology 226 (9), 2378-2390, 2011
1172011
New perspective for an old antidiabetic drug: metformin as anticancer agent
A Leone, E Di Gennaro, F Bruzzese, A Avallone, A Budillon
Advances in Nutrition and Cancer, 355-376, 2014
1132014
Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed
E Di Gennaro, F Bruzzese, S Pepe, A Leone, P Delrio, P Subbarayan, ...
Cancer biology & therapy 8 (9), 782-791, 2009
642009
Local and systemic protumorigenic effects of cancer-associated fibroblast-derived GDF15
F Bruzzese, C Hägglöf, A Leone, E Sjöberg, MS Roca, S Kiflemariam, ...
Cancer research 74 (13), 3408-3417, 2014
592014
Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells
MR Milone, B Pucci, F Bruzzese, C Carbone, G Piro, S Costantini, ...
Cell death & disease 4 (5), e641, 2013
442013
Endothelial progenitor cells, defined by the simultaneous surface expression of VEGFR 2 and CD 133, are not detectable in healthy peripheral and cord blood
P Lanuti, G Rotta, C Almici, G Avvisati, A Budillon, P Doretto, N Malara, ...
Cytometry Part A 89 (3), 259-270, 2016
392016
Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway
A Leone, MS Roca, C Ciardiello, M Terranova-Barberio, C Vitagliano, ...
Free Radical Biology and Medicine 89, 287-299, 2015
362015
Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways
F Bruzzese, B Pucci, MR Milone, C Ciardiello, R Franco, MI Chianese, ...
Cell death & disease 4 (10), e878, 2013
352013
Oxidative stress gene expression profile correlates with cancer patient poor prognosis: identification of crucial pathways might select novel therapeutic approaches
A Leone, MS Roca, C Ciardiello, S Costantini, A Budillon
Oxidative medicine and cellular longevity 2017, 2017
292017
Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression
M Terranova-Barberio, MS Roca, AI Zotti, A Leone, F Bruzzese, ...
Oncotarget 7 (7), 7715, 2016
292016
Enhancement of 5-FU sensitivity by the proapoptotic rpL3 gene in p53 null colon cancer cells through combined polymer nanoparticles
A Russo, S Maiolino, V Pagliara, F Ungaro, F Tatangelo, A Leone, ...
Oncotarget 7 (48), 79670, 2016
252016
Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial
A Avallone, B Pecori, F Bianco, L Aloj, F Tatangelo, C Romano, V Granata, ...
Oncotarget 6 (30), 30394, 2015
192015
Figli per sempre
A Battaglia, A Canevaro, M Chiurchiu, A Leone, MM Pierro, AM Sorrentino
La cura continua del disabile mentale, Carocci Faber, Roma, 2002
182002
Management of non-small cell lung cancer in the era of personalized medicine
G Rocco, A Morabito, A Leone, P Muto, F Fiore, A Budillon
The international journal of biochemistry & cell biology 78, 173-179, 2016
172016
Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep‐2 cancer cells
L Bianchi, F Bruzzese, A Leone, A Gagliardi, M Puglia, E Di Gennaro, ...
Proteomics 11 (18), 3725-3742, 2011
172011
Multidisciplinary approach to rectal cancer: are we ready for selective treatment strategies?
A Avallone, L Aloj, P Delrio, B Pecori, A Leone, F Tatangelo, F Perri, ...
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2013
162013
mTORC1-driven tumor cells are highly sensitive to therapeutic targeting by antagonists of oxidative stress
J Li, S Shin, Y Sun, SO Yoon, C Li, E Zhang, J Yu, J Zhang, J Blenis
Cancer research 76 (16), 4816-4827, 2016
132016
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS …
A Avallone, MC Piccirillo, L Aloj, G Nasti, P Delrio, F Izzo, E Di Gennaro, ...
BMC cancer 16 (1), 69, 2016
122016
Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression
C Ciardiello, MS Roca, A Noto, F Bruzzese, T Moccia, C Vitagliano, ...
Oncotarget 7 (15), 19559, 2016
112016
Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53
M Terranova-Barberio, B Pecori, MS Roca, S Imbimbo, F Bruzzese, ...
Journal of Experimental & Clinical Cancer Research 36 (1), 177, 2017
82017
The system can't perform the operation now. Try again later.
Articles 1–20